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Systematic review of the clinical and genetic aspects 
of Prader-Willi syndrome 
Prader-Willi syndrome (PWS) is a complex multisystem genetic 
disorder that is caused by the lack of expression of paternally inherited 
imprinted genes on chromosome 15q11–q13. This syndrome has 
a characteristic phenotype including severe neonatal hypotonia, 
early-onset hyperphagia, development of morbid obesity, short 
stature, hypogonadism, learning disabilities, behavioral problems, 
and psychiatric problems. PWS is an example of a genetic condition 
caused by genomic imprinting. It can occur via 3 main mechanisms 
that lead to the absence of expression of paternally inherited genes in 
the 15q11.2–q13 region: paternal microdeletion, maternal uniparental 
disomy, and an imprinting defect. Over 99% of PWS cases can be 
diagnosed using DNA methylation analysis. Early diagnosis of PWS 
is important for effective long-term management. Growth hormone 
(GH) treatment improves the growth, physical phenotype, and body 
composition of patients with PWS. In recent years, GH treatment in 
infants has been shown to have beneficial effects on the growth and 
neurological development of patients diagnosed during infancy. There 
is a clear need for an integrated multidisciplinary approach to facilitate 
early diagnosis and optimize management to improve quality of life, 
prevent complications, and prolong life expectancy in patients with 
PWS.
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morbid obesity, short stature, hypogonadism, learning disabilities, 
behavioral problems, and psychiatric problems
3, 4). Whereas earlier 
prevalence estimates in the United States were in the range of 
1 in 8,000–20,000, recent epidemiological surveys in Europe 
and Australia have estimated the lower limit of birth incidence 
at approximately 1 in 30,000 and population prevalence at 
approximately 1 in 50,000
5-8). Recent surveys have highlighted the 
Introduction 
Prader-Willi syndrome (PWS; OMIM 176270) is a complex 
multisystem genetic disorder that occurs due to the lack of expression 
of paternally inherited imprinted genes on chromosome 15q11–q13
1, 
2). The syndrome has a characteristic phenotype including severe 
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high rates and varied causes (respiratory infection or insufficiency, 
unexplained sudden death, choking on food, and central adrenal 
insufficiency) of morbidity and mortality throughout the natural 
course of the disease
9-11). There is a clear need for an integrated 
multidisciplinary approach to facilitate early diagnosis and optimize 
management to improve quality of life, prevent complications, and 
prolong life expectancy in patients with PWS.
Clinical manifestations
1. Characteristics of PWS in the newborn and infant period
Severe hypotonia is consistently observed at birth and during the 
neonatal period (Fig. 1)
12). PWS should thus be considered in all cases 
of neonatal hypotonia. Neonatologists appear to be on the frontline of 
early diagnosis including PWS in the differential diagnosis of severe 
neonatal hypotonia
13). The first stage of PWS, occurring in infancy, is 
characterized by lethargy, marked hypotonia, global developmental 
delay, and small genitalia with frequent cryptorchidism
14). Although 
poor weight gain is typically noted on standard infant growth charts, 
studies have documented excessive body fat in infants with PWS 
by skinfold measurements
15), dual energy-x-ray absorptiometry, and 
doubly labeled water
16). Conversely, lean body mass measurements 
are decreased in PWS infants, correlating with a 30% lower energy 
expenditure as compared to healthy individuals
16). 
2. Dysmorphic features
Patients with PWS have characteristic dysmorphic features 
including a narrow bifrontal diameter, almond-shaped palpebral 
fissures, narrow nasal bridge, and thin upper lip with a down-turned 
mouth (Fig. 2). These patients very commonly have shorter total 
hand size, narrow palms with hypoplastic hypothenar bulges, and 
short feet with short toes. Fair hair and hypopigmentation of the eyes 
and skin relative to other family members are frequently observed in 
patients with deletion-type PWS; these features are less commonly 
observed in patients with uniparental disomy. 
3. Developmental and cognitive delays
Gross motor and language milestones are delayed. Early milestones 
are reached on average at double the normal age (e.g., sitting at 12 
months, walking at 24 months, and words at 2 years). Cognitive 
disability is evident by school age. Most patients with PWS are mildly 
mentally retarded (mean intelligence quotient (IQ): 60–70 score), 
with approximately 40% having borderline mental retardation or 
low-normal intelligence and approximately 20% having moderate 
retardation
17-19). Impaired physical function in PWS patients during 
childhood is most often related to body composition abnormalities 
and hypotonia, rather than to linear growth deficits. 
4. Hyperphagia and obesity
Obesity typically begins between 1 and 4 years of age. During later 
childhood, a seemingly insatiable appetite (hyperphagia) begins. This 
hyperphagia is hypothalamic in origin, caused by a lack of sense of 
satiety
20, 21). Food seeking is common, and if intake is not controlled 
externally, central obesity results from these behaviors combined 
with a low metabolic rate and decreased activity level (that result in 
a decreased total caloric requirement). Body composition studies 
demonstrated both increased body fat and reduced muscle mass in 
patients with PWS from infancy to adulthood.
5. Sleep abnormalities
Individuals with PWS have sleep-disordered breathing, including 
Fig. 1. Hypotonia of infancy in patients with PWS. Note the head-lag 
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central and obstructive sleep apnea, abnormal arousal, abnormal 
circadian rhythms in rapid eye movement (REM) sleep, reduced 
REM latency, and abnormal response to hypercapnia as well as 
excessive daytime sleepiness
22). Obesity can worsen the sleep disorder.
6. Behavioral and psychiatric disturbances
A characteristic behavioral pattern begins in early childhood in 
70–90% of affected individuals. It is typified by temper tantrums, 
stubbornness, controlling and manipulative behavior, compulsive-like 
behaviors (repeated organizing, writing, collecting, and need to finish 
1 thing before moving to the next), and difficulty with changes in 
routine
17). Autism spectrum disorder, attention deficit/hyperactivity 
symptoms, and insistence on sameness are common and of early 
onset
23, 24).
7. Endocrinological abnormalities
1) Obesity
Obesity in PWS is the major cause of morbidity and mortality: 
cardiorespiratory failure, cor pulmonale exacerbated by obstructive 
and central apnea, septicemia due to skin infections, and pneumonia
9, 
11). Appropriate consultation with cardiologists and pneumonologists 
in cases of severely obese individuals is essential. A number of reports 
suggest that glucose tolerance is abnormal in individuals with 
PWS. Fasting plasma insulin concentrations and insulin response 
to glucose are often increased in affected individuals, suggesting 
insulin resistance. Type 2 diabetes mellitus has been reported in 
approximately 25% of adults with PWS with a mean age of onset 
of approximately 20 years of age
25); it appears logical to approach 
diabetes management including weight loss and increased exercise 
by using similar pharmacological agents as those used for non-PWS 
obesity-related diabetes.
2) Growth deficiency
Short stature is usually observed, especially during the second year, 
because of growth hormone (GH) insufficiency exacerbated by the 
lack of a pubertal growth spurt. The serum levels of IGF-I are reduced 
in majority of children with PWS. Spontaneous GH secretion is 
reduced, and the GH peak during pharmacological stimulation 
testing is less than 10 ng/mL in 70% of children
26). Adults with PWS 
have lower stimulated GH secretion than obese controls, but the 
precise prevalence of severe GH deficiency is unclear because reference 
ranges are unavailable for severe obesity. The mean spontaneous adult 
height has been reported as 162 cm in men
27) and 149 cm in women
28) 
in German cohorts. GH treatment in children with PWS improves 
growth during childhood, adult height, and body composition. 
3) Hypogonadism
Hypogonadism is a consistent feature in both men and women 
with PWS; this is manifested as genital hypoplasia throughout life, 
incomplete pubertal development, and infertility in the vast majority 
of cases. In men, the penis may be small, but the most characteristic 
feature is a hypoplastic scrotum that is small, poorly rugated, and 
poorly pigmented. Unilateral or bilateral cryptorchidism is present in 
80–90% of affected men. In women, the labia (majora and minora) 
and clitoris are generally hypoplastic. Most individuals will have no, 
delayed, and/or incomplete puberty. Isolated premature pubarche 
(probably due to early maturation of the zona reticularis of the 
adrenal gland) and precocious puberty have been reported in 14% 
and 4% of males and females, respectively
29, 30). Hypogonadism is of 
hypothalamic origin, and generally, there is hypogonadotropism with 
decreased testosterone or estrogen and decreased follicle-stimulating 
hormone and luteinizing hormone levels in both genders. There is no 
consensus on the management of these conditions.
Fig. 3. Summary of the genetic and expression map of chromosomal region 15q11.2–q13. There 
are 6 paternal-only (PWS region) expressed unique copy genes (MKRN3, MAGEL2, NECDIN, 
C15ORF2, and SNRPN and a family of 5 paternal-only expressed snoRNA genes). Only UBE3A and 
ATP10A, related to Angelman syndrome (AS), have maternal-only expression in mice and humans. 
The bipartite imprinting center lies proximal to SNRPN and within the 3-Mb PWS/AS imprinted 
region. The cluster of GABA receptor genes (GABRB3, GABRA5, and GABRG3), OCA2 (type II 
albinism), and HERC2 are not imprinted and have biparental expression. Type 1 deletions extend 
from BP1 to BP3, and type 2 deletions extend from BP2 to BP3 (Cassidy et al. 2009 Eur J Hum 
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Molecular and genetic basis of PWS
PWS is an example of a genomic disorder, as it results from 
alterations in the structure of the genome (an epigenetic phenomenon) 
and not a specific change in the DNA sequence
31). The various 
genomic changes causing PWS lead to the loss of expression of the 
paternally expressed genes on chromosome 15q11.2–q13 through 
loss or failure of expression; this is because the maternal contribution 
has been programmed by epigenetic factors (e.g., DNA methylation) 
to be silenced
32). PWS and Angelman syndrome are the first known 
examples of human diseases involving imprinted genes
33).
1. Structure and genes in the 15q11–q13 region
The 15q11.2–q13 region is highly complex and contains a number 
of imprinted and non-imprinted genes (Fig. 3). The majority of 
patients with deletions have 1 of 2 common proximal breakpoints 
(BP1 and BP2) and a common distal breakpoint (BP3)
34-36). The 
paternally expressed genes are located in the more centromeric part 
of the region. These are MKRN3; MAGEL2; NDN; C15orf2; 
SNURF-SNRPN (typically referred to as SNRPN); and the C/D 
box small nucleolar RNA (snoRNA) genes SNORD107 (previously 
HBII-436), SNORD64 (previously HBII-13), SNORD108 
(previously HBII-437), SNORD109A (previously HBII-438A), 
SNORD116 (previously HBII-85), SNORD115 (previously HBII-
52), and SNORD109B (previously HBII-438B). SNORD115 
and SNORD116 are present as multicopy gene clusters, whereas 
the other snoRNA genes are single-copy genes. In contrast to 
other C/D box snoRNAs, which are usually involved in the 
modification of ribosomal RNAs, these snoRNAs do not have a 
region complementary to ribosomal RNA and might be involved 
in the modification of mRNAs, probably by modulating alternative 
splicing
37-39). Paternal-only expression of MKRN3, NDN, and 
SNRPN is regulated by parent-of-origin-specific DNA methylation 
of the promoter regions of each gene. Whereas the active paternal 
allele is unmethylated, the inactive maternal allele is methylated. 
The most complex gene in the 15q11–q13 region is SNRPN. 
The original gene, found to consist of 10 exons, encodes 2 different 
proteins. Exons 1–3 encode SNURF, a small polypeptide of 
unknown function
40), while exons 4–10 encode SmN, a spliceosomal 
protein involved in mRNA splicing in the brain
41). Many 5´ and 3´ 
exons of SNRPN have been identified. These exons have 2 peculiar 
features: They do not have any protein coding potential, and they 
occur in many different splice forms of the primary transcript
33). 
According to recent reports, the SNORD116 locus is probably a 
major gene contributing to the PWS phenotype
42-44). It is likely, 
however, that 1 or more additional genes in the region also contribute 
to the phenotype.
1) Microdeletions of the chromosome region 15q11–q13 
A 5–7-Mb de novo deletion of the proximal region of the paternal 
chromosome 15 [del(15)(q11–q13)], which includes the entire 
imprinted domain plus several non-imprinted genes, is found in 
the majority (~70%) of patients with PWS. At the molecular level, 
usually 2 classes of deletions (class I and II) can be distinguished, 1 
spanning from BP1 to BP3 and the other from BP2 to BP3 (Fig. 3). A 
precise localization of the deletion breakpoints and the determination 
of the deletion sizes have been performed by array-CGH analysis 
recently
45-47).
2) Uniparental disomy of chromosome 15
The second most common genetic abnormality in PWS (~25–
30%) is a maternal uniparental disomy of chromosome 15 [upd(15)
mat], occurring mostly due to maternal meiotic nondisjunction 
followed by mitotic loss of the paternal chromosome 15 after 
fertilization
31). Upd(15)mat leads to the lack of expression of imprinted 
genes that are active on the paternal chromosome only. 
3) Imprinting defect 
Disruption of the imprinting process on the paternally inherited 
chromosome 15 is the third molecular mechanism underlying 
PWS (Fig. 4). This disruption is present in approximately 2–5% of 
individuals. Most imprinting defects are epigenetic (epimutations) 
and demonstrate a maternal-only DNA methylation pattern despite 
the presence of both parental alleles (biparental). DNA sequence 
changes are not found in these epimutations; they are thought to be 
random stochastic errors occurring during spermatogenesis in the 
fathers
48). By contrast, approximately 15% of individuals with an 
imprinting defect are found to have a very small deletion in the PWS 
imprinting center region located at the 5´ end of the SNRPN gene.
Diagnostic testing 
Parent-of-origin-specific DNA methylation can be used to confirm 
Fig. 4. Molecular classes of PWS and their frequencies (Buiting et al. 
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the clinical diagnosis of PWS patients in all 3 molecular classes 
(deletion of 15q11-q13, uniparental disomy, and imprinting defect). 
The most widely used DNA methylation test targets the 5´ end of the 
SNRPN locus
49, 50). The promoter region of SNRPN is unmethylated 
on the paternally expressed allele and methylated on the maternally 
repressed allele. Normal individuals have both a methylated and an 
unmethylated allele, whereas individuals with PWS have only the 
maternally methylated allele. DNA methylation cannot distinguish 
this molecular class. Deletion of the paternally contributed 15q11.2–
q13 is typically diagnosed using the SNRPN fluorescence in situ 
hybridization probe
32). Chromosome analysis should be included 
in testing for a deletion, as occasionally the deletion is the result 
of a chromosomal translocation. Maternal uniparental disomy is 
diagnosed using DNA polymorphism analysis of the proband and 
parental DNA.
Treatment
Patients with PWS frequently require medical care. Initial 
management of hypotonia or poor feeding, evaluation for hypo-
gonadism or hypopituitarism, management of obesity, monitoring for 
scoliosis, and therapy for behavioral issues are needed
51). Currently, no 
medications have been found to effectively modify hyperphagia. Sex 
steroid supplementation does improve secondary sex characteristics 
but may aggravate behavioral disorders
52).
1. GH therapy in patients with PWS 
On June 20, 2000, the US Food and Drug Administration 
approved the use of GH in children with genetically confirmed 
PWS and the evidence of growth failure
53). GH deficiency has been 
well documented in PWS by GH response testing with decreased 
GH response, relatively low IGF-1 levels, and abnormal body 
composition with high fat mass and low lean body mass. Numerous 
beneficial effects of GH therapy have been documented, including 
improvement in linear growth, physical appearance, functional 
muscle mass, and infant neurodevelopment. However, GH therapy 
does not appear to enhance the development of scoliosis, and it 
anecdotally modulates behavior in some patients
52-54). Treatment of 
adult PWS patients with GH is under investigation and appears to 
be promising
55). Currently, the recommended dose of GH is 24 U/
m
2 per week (1.0 mg/(m
2 . day) for patients over 2 years of age. Korean 
insurance covers patients diagnosed with PWS by clinical symptoms 
and genetic testing; Genotropin (somatotropin (rDNA origin) for 
injection, Pfizer) is used for treatment. The optional dose of GH 
covered by Korean insurance is 0.035 mg/(kg
 . day) or 1 mg/(m
2 . day) 
(but less than 2.7 mg/day). Treatment is covered from over 2 years of 
age, until the bone age is 14–15 years in girls and 15–16 years in boys. 
Once a female’s height reaches 150 cm or a male’s height reaches 160 
cm, insurance coverage is no longer provided in Korea. Then, after 
a GH stimulation test, if the patient has GH deficiency, the patient 
can continue GH treatment with the adult dosage (2 U/day), which is 
covered by insurance.
2. GH therapy in infants with PWS
Although GH therapy in PWS has various beneficial effects, 
body composition and physical function (muscle strength and 
agility) remain abnormal even after 4 years of GH therapy, with 
high doses given the last 2 years
56). These persistent manifestations 
of the syndrome might reflect non-GH-related abnormalities 
intrinsic to PWS and/or the late initiation of GH therapy following a 
critical period of adipose and muscle development during infancy
14). 
Therefore, it is important to evaluate the effects of early GH therapy 
on the physical findings and neurodevelopment of infants and 
toddlers with PWS. 
In 1 study including similar-aged children with PWS who 
had received or not received long-term GH therapy, the strongest 
evidence to date showed that GH therapy, when started early in life, 
beneficially and significantly altered the natural history of PWS by 
reducing body fat and improving muscle strength physical function, 
and lipid profiles without adverse effects
57). Thus, physicians and 
families can favorably weigh the sustained long-term value of GH 
treatment in infantile patients with PWS. Some experts advise that 
GH treatment should be started at a low dose such as 0.25–0.30 
mg/(m
2 ∙ day) or 0.009–0.012 mg/(kg ∙ day) and increased during 
the first weeks and months to reach the standard replacement GH 
dose of approximately 1.0 mg/(m
2 ∙ day) or 0.035 mg/(kg ∙ day) with 
the monitoring of clinical effects, such as sleep apnea and increase 
in the level of IGF-I, particularly if there is a clinical suspicion of 
overtreatment (edema, worsening or new development of snoring, 
headache, and/or acromegalic clinical features)
51). In recent years, 
the diagnosis of PWS during infancy has increased. At the Samsung 
Medical Center, there are nearly 180 patients with PWS, and 86 
patients were diagnosed during infancy. Although children younger 
than 2 years of age are not covered by health insurance in Korea, 
GH therapy has been started in infants after obtaining informed 
consent from their parents in recent years. Their growth curve and 
development relative to chronologic age have improved with GH 
therapy. There have been no severe side effects. However, a long-term 
follow-up of the patients treated with GH may be needed. 60      KY Jin • Systematic Review of the Clinical and Genetic Aspects of Prader-Willi Syndrome  
3. Mechanism of the effects of GH therapy in infants with 
PWS
In a randomized, controlled trial, administration of GH to infants 
and toddlers with PWS normalized height, increased accrual of lean 
body mass, and reduced the percent body fat after 1 year of treatment. 
The 2-year data showed that the accumulation of excess body fat was 
delayed and reduced but not prevented, similar to an earlier study 
reporting a body fat SDS of +3 after 2.5 years of GH treatment
60). 
The age at independent walking was younger than typical for the 
syndrome, 23.3±4.8 months in this study and 24.1 months in a 
previous study
61). Subjectively, the GH-treated infants and toddlers 
were reported to be more alert and energetic by their families. An 
increased rate of language and cognitive development in the treated 
group was noted. It is unclear whether these results are solely from 
the known effects of GH therapy on muscle tone. However, the 
concomitant increase in head growth suggests that a central nervous 
system effect may also play a role
14). In 1 study, IGF-I levels increased 
rapidly during GH treatment from below the normal range to 
the high-normal range
62). IGF-I receptors have been localized in 
several areas of the human brain, indicating that IGF-I may have a 
neuroregulatory role in the central nervous system
63). Theoretically, 
IGF-I may directly influence the central nervous system or GH might 
induce local IGF-I expression in brain tissue, thereby improving 
psychomotor development
62). Another possible explanation for the 
improvement in mental development during GH treatment might be 
that because of the improved motor development, children are able 
to sit, stand, and walk independently, enabling them to explore and 
interact with the environment, resulting in subsequent improvement 
in mental development
62).
In another study, after 1 year of GH treatment, there was a signifi-
cant improvement in both mental and motor development in PWS 
infants and toddlers compared to randomized controls
62). Head 
circumference increased from low-normal to normal during GH 
treatment. Children with an initially lower motor developmental age 
improved more than children with a higher initial motor develop-
mental age, indicating that early treatment with GH might be 
beneficial. In the general population, there is evidence that intelligence 
tends to be higher in subjects with a greater head circumference, 
and brain growth during infancy and early childhood appears to be 
more important than that during fetal life in determining cognitive 
function
64).
4. Concerns in GH therapy 
Children with PWS are at risk of developing sleep-disordered 
breathing secondary to both deficient autonomic sleep control and 
upper airway obstruction. It has been suggested that GH exacerbates 
preexisting gas-exchange deficiencies in 3 ways: by stimulating 
adenotonsillar hypertrophy
65), increasing the basal metabolic rate 
with a resultant rise in oxygen demand
66), and normalizing previously 
decreased hydration with an augmentation of the volume load
67). 
A causal relationship between GH and sudden death has not been 
demonstrated, although important concerns over safety have been 
raised. Concerns over possible worsening of obstruction are justified 
in the obese group, and patients with PWS require careful dietary, 
ENT, and respiratory evaluation before starting treatment with GH. 
Selected cases may benefit from noninvasive ventilatory support. 
Complications and Prognosis
Patients with PWS can develop complications associated with 
hypogonadism (osteoporosis/pathological fractures) and obesity due 
to hyperphagia and hypometabolism (secondary to hypopituitarism), 
predisposing these patients to premature death from cardiorespiratory 
failure. They can also develop slipped capital femoral epiphyses/hip 
dysplasia, sleep apnea, cor pulmonale, and type 2 diabetes mellitus. 
Various neoplasias have been rarely reported in patients with PWS. 
In addition, because of binge-eating episodes, patients may have 
choking episodes (requiring the Heimlich maneuver), acute gastric 
dilation with risk of gastric necrosis, and food poisoning from the 
consumption of contaminated food
69).
Patients with PWS frequently reach adulthood and are able to 
function in a group home setting, performing vocational work or 
attending community college classes. Diminished sensitivity to 
pain and diminished capacity to vomit may delay the diagnosis 
of underlying diseases (e.g., appendicitis). Complications from 
hypogonadism (e.g., osteoporosis/pathological fracture), behavioral 
issues (e.g., temper tantrums, stubbornness, and psychoses), and 
morbid obesity (e.g., type 2 diabetes mellitus and cor pulmonale) may 
shorten life expectancy and affect the quality of life. Patients with 
PWS can be mainstreamed into the classroom environment. They 
require additional speech therapy to enhance verbal skills and should 
have additional physical activity periods in place of rest periods. These 
individuals require a structured environment and may need a smaller 
classroom size for individual attention. Older children with PWS 
may enter vocational programs (with avoidance of food preparation). 
Some adults have attended community colleges.
Conclusion
The complex genetics, etiology, multiple phenotypes, and evolving 
natural history of PWS suggest that a multidisciplinary professional, 
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of these patients is required for overcoming the many challenges of 
reducing morbidity and mortality and improving patient quality 
of life. GH replacement therapy in PWS has resulted in drastic 
improvements in the phenotype, body composition, and self-image 
of treated individuals. However, much is yet to be learned about 
this complex disorder. It has been 27 years since the genetic region 
responsible for PWS was first identified, yet we still do not know the 
precise gene(s) responsible for the phenotype. Recent data suggest 
a key role of the HBII-85 snoRNA gene, and in the near future, 
researchers should uncover its gene targets, leading to improved 
treatments. 
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